HIF1A and neoplasm: These are compelling results illustrating that the CDP technology can significantly modulate the pharmacokinetics, and consequently the pharmacodynamics, of CPT to enhance its efficacy with prolonged drug exposure [16], i.e. keeping CPT in its active form, increasing tumor drug concentrations, augmenting intracellular drug concentration, and maintaining drug supply in target cells over longer periods of time to sustain Topo 1 and possibly HIF-1α inhibition.